journal
MENU ▼
Read by QxMD icon Read
search

Immunotherapy

journal
https://www.readbyqxmd.com/read/29145737/pembrolizumab-as-first-line-therapy-for-metastatic-non-small-cell-lung-cancer
#1
Martin Reck
This review describes trials evaluating the monoclonal antibody pembrolizumab (an immunotherapy that blocks the interaction between programmed death-1 and programmed death-ligand 1 and 2 [PD-L1/PD-L2]) as first-line therapy for advanced non-small-cell lung cancer (NSCLC). In the Phase III KEYNOTE-024 study, pembrolizumab monotherapy significantly improved progression-free survival (primary end point) and overall survival, and was associated with fewer adverse events compared with platinum-based chemotherapy in patients with NSCLC with PD-L1 expression on ≥50% of tumor cells...
November 17, 2017: Immunotherapy
https://www.readbyqxmd.com/read/29124994/a-review-on-biosimilar-infliximab-ct-p13-in-the-treatment-of-inflammatory-bowel-disease
#2
Klaudia Farkas, Tamás Molnár
The introduction of biological agents has led to significant changes in the treatment of inflammatory bowel disease (IBD). The relatively high price of infliximab (IFX) and the expiration of the patents led to the introduction of biosimilar agents. CT-P13 was the first IFX biosimilar approved in the same indications as the reference product; however, the approval was based on randomized clinical trials conducted in patients with rheumatoid arthritis and ankylosing spondylitis. In the past 2-3 years, new findings from prospective observational studies supported the short-, medium- and long-term clinical efficacy and safety of CT-P13 in patients with IBD...
November 10, 2017: Immunotherapy
https://www.readbyqxmd.com/read/29064334/drug-device-evaluation-review-melanoma-treatment-with-intratumoral-electroporation-of-tavokinogene-telseplasmid-pil-12-tavokinogene-telseplasmid
#3
David A Canton, Shawna Shirley, Jocelyn Wright, Richard Connolly, Christoph Burkart, Anandaroop Mukhopadhyay, Chris Twitty, Kristen E Qattan, Jean S Campbell, Mai H Le, Robert H Pierce, Sharron Gargosky, Adil Daud, Alain Algazi
Tumors evade detection and/or clearance by the immune system via multiple mechanisms. IL-12 is a potent immunomodulatory cytokine that plays a central role in immune priming. However, systemic delivery of IL-12 can result in life-threatening toxicity and therefore has shown limited efficacy at doses that can be safely administered. We developed an electroporation technique to produce highly localized IL-12 expression within tumors leading to regression of both treated and untreated lesions in animal models and in patients with a favorable safety profile...
October 24, 2017: Immunotherapy
https://www.readbyqxmd.com/read/29064314/rituximab-in-pemphigus
#4
Vivien Hebert, Pascal Joly
Pemphigus is a severe autoimmune blistering disease mediated by pathogenic anti-desmoglein antibodies leading to an inter keratinocyte disjunction. Rituximab is a monoclonal antibody that binds to the CD-20 antigen of B lymphocytes, which causes B-cell depletion and a subsequent reduction in pathogenic autoantibodies. Its therapeutic role in pemphigus has been progressively growing with increasing evidence of successful outcomes. Rituximab was initially off-labeled used as an alternative in patients with recalcitrant or relapsing pemphigus and in patients with contraindications to systemic corticosteroids...
October 24, 2017: Immunotherapy
https://www.readbyqxmd.com/read/29043892/tofacitinib-in-the-treatment-of-active-rheumatoid-arthritis-in-adults
#5
Roy Fleischmann
Tofacitinib, a pan Janus kinase inhibitor, has been investigated as monotherapy in patients naive to methotrexate and in methotrexate incomplete responders and in combination with disease-modifying antirheumatic drugs in antirheumatic drug incomplete responders and TNF inhibitor failures in the Phase II and III programs. The clinical trial program demonstrated efficacy and a reasonable safety profile in these disease populations that has led to the approval of tofacitinib 5 mg twice daily orally in many countries...
October 18, 2017: Immunotherapy
https://www.readbyqxmd.com/read/29043884/guselkumab-for-psoriasis-a-critical-appraisal-of-phase-iii-studies
#6
Zenas Zn Yiu, Richard B Warren
Biologic therapies have raised the frontiers of accepted treatment efficacy for severe psoriasis. Guselkumab is an IgG1 monoclonal antibody that binds to the p19 subunit and inhibits IL-23. In three Phase III randomized, active comparator and placebo controlled trials, guselkumab demonstrated superior efficacy and a comparable safety profile when assessed against adalimumab and ustekinumab. Critical appraisal highlighted uncertainties over risk of bias from missing details in the trial publications that would be overcome with the provision of accompanying trial protocols, as well as the need for a head-to-head trial against an IL-17 inhibitor...
October 18, 2017: Immunotherapy
https://www.readbyqxmd.com/read/29043871/a-review-of-sarilumab-for-the-treatment-of-rheumatoid-arthritis
#7
Eun Bong Lee
Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease predominantly affecting the peripheral diarthrodial joints. Sarilumab is a human monoclonal antibody against the IL-6 receptor-α. In Phase II and III clinical trials, sarilumab in the background of methotrexate showed superior clinical efficacy over placebo in RA patients with inadequate response to methotrexate or inadequate response or intolerance to TNF inhibitors. Sarilumab monotherapy also showed superior efficacy compared with adalimumab monotherapy in RA patients with inadequate response or intolerance to methotrexate...
January 2018: Immunotherapy
https://www.readbyqxmd.com/read/28967798/tofacitinib-in-psoriatic-arthritis
#8
Ting-Shun Wang, Tsen-Fang Tsai
Psoriatic arthritis is a heterogeneous disease that has been difficult to manage until the recent advent of biologics. However, there are still unmet medical needs for newer agents. Tofacitinib is a Janus family of kinases inhibitor approved for treating rheumatoid arthritis in many countries and psoriasis in Russia. We reviewed the evidences of tofacitinib in psoriatic arthritis treatment. The efficacy and safety profiles result from Phase III clinical trials (OPAL BROADEN and OPAL BEYOND) and one open-label extension study (OPAL BALANCE)...
October 2, 2017: Immunotherapy
https://www.readbyqxmd.com/read/28967793/fostamatinib-for-persistent-chronic-adult-immune-thrombocytopenia
#9
Adrian Newland, Eun-Ju Lee, Vickie McDonald, James B Bussel
Immune thrombocytopenia (ITP) is an acquired autoimmune disorder characterized by phagocytosis and destruction of autoantibody-coated platelets via spleen tyrosine kinase (Syk)-mediated signal transduction in macrophages. Effectiveness of existing therapies varies, and even leading treatments (e.g., IVIg, splenectomy, rituximab, thrombopoietic agents) do not provide optimal management for a substantial number of patients with chronic ITP. Fostamatinib disodium is an orally-bioavailable investigational agent being developed for treatment of primary persistent/chronic adult ITP...
October 2, 2017: Immunotherapy
https://www.readbyqxmd.com/read/29192558/spleen-tyrosine-kinase-inhibition-a-new-promising-approach-to-chronic-and-refractory-immune-thrombocytopenia
#10
Pasquale Niscola, Laura Scaramucci, Marco Giovannini
No abstract text is available yet for this article.
January 2018: Immunotherapy
https://www.readbyqxmd.com/read/29192557/message-from-the-editor-welcome-to-the-10th-volume-of-immunotherapy
#11
Sonia Mannan
No abstract text is available yet for this article.
January 2018: Immunotherapy
https://www.readbyqxmd.com/read/29185395/pd-l1-expression-in-tumor-metastasis-is-different-between-uveal-melanoma-and-cutaneous-melanoma
#12
Asad Javed, David Arguello, Curtis Johnston, Zoran Gatalica, Mizue Terai, Ryan M Weight, Marlana Orloff, Michael J Mastrangelo, Takami Sato
AIM: To compare PD-L1 expression between metastatic uveal melanoma (MUM) and metastatic cutaneous melanoma (MCM). MATERIALS & METHODS: A total of 295 MCM and 78 MUM specimens were analyzed for tumor cell PD-L1 expression. Additionally, 91 MCM and 45 MUM specimens were analyzed for PD-1 expression on tumor-infiltrating lymphocytes. RESULTS:  A total of 77/295 (26.1%) MCM specimens expressed PD-L1 as compared to 4/78 (5.1%) MUM specimens (p < 0...
December 2017: Immunotherapy
https://www.readbyqxmd.com/read/29185394/modulation-of-immunosurveillance-by-tumor-intrinsic-genomic-alterations
#13
Craig Furman, Ping Zhu, Manav Korpal
No abstract text is available yet for this article.
December 2017: Immunotherapy
https://www.readbyqxmd.com/read/29185393/chimeric-switch-receptor-switching-for-improved-adoptive-t-cell-therapy-against-cancers
#14
Johan Ck Tay, Shijun Zha, Shu Wang
Adoptive T-lymphocyte transfer-based immunotherapy for cancers has seen huge leaps with both CARs and engineered TCRs. Despite this, issues relating to safety and efficacy persist. To address this, chimeric switch receptors have been created to reverse the outcomes of their original signaling pathways in order to confer immune cells with the ability to overcome the immunosuppressive tumor microenvironment and to allow them to have greater in vivo persistence. Activating switch receptors exploit the inhibitory molecules expressed by cancer cells to further stimulate the tumor antigen-specific T lymphocytes...
December 2017: Immunotherapy
https://www.readbyqxmd.com/read/29185392/immunotherapy-in-head-and-neck-cancer-evidence-and-perspectives
#15
Alicia Tosoni, Enrico Franceschi, Ernesto Pasquini, Andrea Lanese, Elisa Donini, Maria Pia Foschini, Danilo Dall'Olio, Alba A Brandes
Head and neck squamous cell carcinomas evade immune response through multiple immunologic resistance mechanisms. Two of the most commonly involved checkpoint inhibitory mechanisms are CTLA-4 and PD-1/PD-L1, which act at earlier and later stages of immune response to tumors. Pembrolizumab and nivolumab are PD-1 antibodies that interrupt the immunosuppressive pathway of inhibitory checkpoints, which are used by tumor cells to prevent immune reaction. Both recently gained US FDA approval for the treatment of patients with recurrent or metastatic head and neck cancer with disease progression during or following platinum containing chemotherapy...
December 2017: Immunotherapy
https://www.readbyqxmd.com/read/29185391/current-status-of-immunotherapy-for-sarcomas
#16
Shinji Miwa, Hideji Nishida, Hiroyuki Tsuchiya
Although the development of anticancer drugs has improved the outcomes of bone and soft tissue sarcomas, the clinical outcome of patients with relapsed sarcomas remains unsatisfactory due to therapeutic toxicities and resistance to anticancer drugs. Therefore, novel therapeutic modalities are needed to improve the outcome of patients with bone and soft tissue sarcomas. Dendritic cells present tumor antigens and stimulate immune responses, and immune cells, such as cytotoxic T lymphocytes, kill tumor cells by recognizing tumor antigens...
December 2017: Immunotherapy
https://www.readbyqxmd.com/read/29185390/modulation-of-antitumor-immunity-with-histone-deacetylase-inhibitors
#17
Tyler R McCaw, Troy D Randall, Andres Forero, Donald J Buchsbaum
Histone deacetylase inhibitors possess a broad array of antitumor activities; however, their net impact on the evolving antitumor immune response is highly dependent on the inhibitors used and the histone deacetylases they target. Herein, we sequentially focus on each stage of the antitumor immune response - from dendritic cell activation and migration, antigen uptake and presentation, T-cell activation and differentiation and the enactment of antitumor effector functions within the tumor microenvironment. In particular, we will discuss how various inhibitors have different effects depending on cellular activation, experimental design and specific histone deacetylases being targeted - and how these changes impact the outcome of an antitumor immune response...
December 2017: Immunotherapy
https://www.readbyqxmd.com/read/29130803/steroid-sparing-effect-of-sublingual-immunotherapy-real-life-study-in-mono-polisensitized-children-with-asthma
#18
Nerin Nadir Bahceciler, Nilufer Galip, Arzu Babayigit
AIM: Steroid-sparing effect of sublingual immunotherapy (SLIT) in mono/polisensitized asthmatic children were evaluated. MATERIALS AND METHODS:  Children undergoing allergen-specific SLIT between 2010 and 2014 were included. Asthma control and usage/dose of inhaled corticosteroid (ICS) in the previous year was determined. Asthma control without ICS need ≥6 months was defined as 'ICS avoidance'. RESULTS:  90 children (mean ± SD age 8...
November 2017: Immunotherapy
https://www.readbyqxmd.com/read/29130802/oral-immunotherapy-using-polymeric-nanoparticles-loaded-with-peanut-proteins-in-a-murine-model-of-fatal-anaphylaxis
#19
Carlos Gamazo, Maddi García-Azpíroz, Juliana De Souza Rebouças, Gabriel Gastaminza, Marta Ferrer, Juan M Irache
BACKGROUND: Peanut allergy is the most common cause of anaphylaxis and food-related death. However, there is currently no approved immunotherapy treatment. Hence, this warrants the need for relevant and convenient animal models to test for adequate immunotherapies. MATERIALS & METHODS: In this study, we compared three mouse strains: CD1, BALB/c and C57, to select a model of peanut allergy. After that, we conducted then a therapeutic study using an immunogenic peanut extract encapsulated in nanoparticles made with polymer Gantrez(®) following the solvent displacement method...
November 2017: Immunotherapy
https://www.readbyqxmd.com/read/29130801/the-relevance-of-house-dust-mites-allergy-in-clinical-practice-the-epidemiological-impact-on-allergen-immunotherapy
#20
Giorgio Ciprandi, Paola Puccinelli, Cristoforo Incorvaia, Giovanni Passalacqua
House dust mite (HDM) is the most common cause of respiratory allergy worldwide. The impact of HDM allergy is influenced by a number of factors, including local climate. We investigated such issue in Italy, using a real-life setting, including outpatients visited at allergy clinics. In 9143 patients (7873 adults and 1270 children) who were evaluated in 15 allergy clinics, investigating as well the rate of prescription of allergen immunotherapy. The present study confirms that Mediterranean climate is associated with a higher prevalence of mite allergy than continental climate...
November 2017: Immunotherapy
journal
journal
42164
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"